[theold]

Both CureVac and BioNTech have worked to develop the messenger RNA technology employed in their respective vaccines and potentially for other uses.

CureVac said it filed its suit against BioNTech and two subsidiaries at the state court in Duesseldorf. It asserted in a statement that its intellectual property portfolio “protects multiple inventions that are considered essential to the design and development of BioNTech’s SARS CoV-2 mRNA vaccine, among others.”


https://abcnews.go.com/Business/wireStor...h-86247993